Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026)

Takeda Pharmaceutical's Retained Earnings history runs 10 years deep, the most recent figure standing at $6.7 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 13.45% year-over-year to $6.7 billion; the TTM figure through Mar 2026 stood at $6.7 billion (down 13.45% YoY), while the FY2026 annual figure was $7.0 billion, down 9.97% from the prior year.
• Retained Earnings was $6.7 billion for Q1 2026 at Takeda Pharmaceutical, down from $7.1 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $12.7 billion in Q1 2022 to a low of $6.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged $9.5 billion across 5 years, with a median of $9.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings declined 21.37% in 2022, then declined 3.67% in 2023.
• A 5-year view of Retained Earnings shows it stood at $10.7 billion in 2022, then declined by 11.45% to $9.4 billion in 2023, then declined by 10.14% to $8.5 billion in 2024, then slipped by 16.16% to $7.1 billion in 2025, then decreased by 5.37% to $6.7 billion in 2026.
• The last three Retained Earnings figures came in at $6.7 billion (Q1 2026), $7.1 billion (Q4 2025), and $7.8 billion (Q3 2025), per Business Quant data.